Zhiping Rao
Overview
Explore the profile of Zhiping Rao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
480
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xia Y, Su M, Ye Z, Du F, Wang X, Guan D, et al.
Trends Biotechnol
. 2025 Feb;
PMID: 39955233
Gene therapy is promising for treating genetic disorders, but faces challenges in treating cancer due to the intricate genetic and immunosuppressive landscape of this disease. Here, we describe a technology...
2.
Qiao C, Wang L, Huang C, Jia Q, Bao W, Guo P, et al.
Adv Mater
. 2024 Dec;
37(6):e2412982.
PMID: 39696900
Cysteine metabolism is a key determinant of the defense against ferroptosis in pancreatic ductal adenocarcinoma (PDAC). Blocking cysteine metabolism may trigger potent ferroptosis in PDAC cells by generating lipid peroxides...
3.
Zhang X, Zhang H, Dong Q, Qin Y, Cao Y, Zhu H, et al.
Nano Lett
. 2024 Nov;
24(49):15817-15826.
PMID: 39584561
Hypoxia-induced tumor metastasis severely hinders the efficacy of photodynamic therapy (PDT) in cancer treatment. Current strategies predominantly offer palliative suppression of the HIF-1α pathway, emphasizing the urgent need for innovative...
4.
Yang P, Liu S, Chen Z, Liu W, Duan D, Yang Z, et al.
J Nanobiotechnology
. 2024 Nov;
22(1):670.
PMID: 39487480
Background: Mn-mediated chemodynamic therapy (CDT) has been emerged as a promising cancer therapeutic modality that relies heavily on HCO level in the system. Although the physiological buffers (HCO/HCO) provide certain...
5.
Rao Z, Zhu Y, Chen Z, Luo Y, Yang Z, Liu W, et al.
Adv Sci (Weinh)
. 2024 Oct;
12(1):e2408415.
PMID: 39465669
Modulating immunosuppression while eliminating residual microscopic tumors is critical for inhibiting the postoperative recurrence of triple-negative breast cancer (TNBC). Although immunotherapy has shown potential in achieving this goal, due to...
6.
Rao Z, Xia Y, Jia Q, Zhu Y, Wang L, Liu G, et al.
J Nanobiotechnology
. 2023 Aug;
21(1):265.
PMID: 37563614
Background: Emerging ferroptosis-driven therapies based on nanotechnology function either by increasing intracellular iron level or suppressing glutathione peroxidase 4 (GPX4) activity. Nevertheless, the therapeutic strategy of simultaneous iron delivery and...
7.
Ning P, Yao H, Du F, Yuan J, Xia Y, Yang P, et al.
Mol Pharm
. 2023 Mar;
20(5):2362-2375.
PMID: 36989419
Efficient drug delivery to solid tumors remains a challenge. HER2-positive (HER2) tumors are an aggressive cancer subtype with a resistance to therapy, high risk of relapse, and poor prognosis. Although...
8.
Rao Z, Lu C, Fan H, Du F, Zhu Y, Xia Y, et al.
Adv Healthc Mater
. 2023 Mar;
12(18):e2203356.
PMID: 36929306
The majority of cancer patients die of metastasis rather than primary tumors, and most patients may have already completed the cryptic metastatic process at the time of diagnosis, making them...
9.
Rao Z, Zhu Y, Yang P, Chen Z, Xia Y, Qiao C, et al.
Theranostics
. 2022 Jun;
12(9):4310-4329.
PMID: 35673561
Pyroptosis is a lytic and inflammatory type of programmed cell death that is usually triggered by inflammasomes and executed by gasdermin proteins. The main characteristics of pyroptosis are cell swelling,...
10.
Liu F, Zhang Y, Chen F, Yuan J, Li S, Han S, et al.
Cell Death Dis
. 2021 Mar;
12(3):225.
PMID: 33649354
Conversion of astrocytes into neurons in vivo offers an alternative therapeutic approach for neuronal loss after injury or disease. However, not only the efficiency of the conversion of astrocytes into...